Killer Cells, Lymphokine-Activated
"Killer Cells, Lymphokine-Activated" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cytolytic lymphocytes with the unique capacity of killing natural killer (NK)-resistant fresh tumor cells. They are INTERLEUKIN-2-activated NK cells that have no MAJOR HISTOCOMPATIBILITY COMPLEX restriction or need for antigen stimulation. LAK cells are used for ADOPTIVE IMMUNOTHERAPY in cancer patients.
MeSH Number(s)
A11.118.637.555.283.500
A11.118.637.555.567.537.500
A15.145.229.637.555.283.500
A15.145.229.637.555.567.537.500
A15.382.490.555.283.500
A15.382.490.555.567.537.500
Concept/Terms
Killer Cells, Lymphokine-Activated- Killer Cells, Lymphokine-Activated
- Cell, Lymphokine-Activated Killer
- Cells, Lymphokine-Activated Killer
- Killer Cell, Lymphokine-Activated
- Killer Cells, Lymphokine Activated
- Lymphokine-Activated Killer Cell
- Lymphokine-Activated Killer Cells
- Lymphokine Activated Killer Cells
- LAK Cells
- Cell, LAK
- Cells, LAK
- LAK Cell
Below are MeSH descriptors whose meaning is more general than "Killer Cells, Lymphokine-Activated".
- Anatomy [A]
- Cells [A11]
- Blood Cells [A11.118]
- Leukocytes [A11.118.637]
- Leukocytes, Mononuclear [A11.118.637.555]
- Cytokine-Induced Killer Cells [A11.118.637.555.283]
- Killer Cells, Lymphokine-Activated [A11.118.637.555.283.500]
- Lymphocytes [A11.118.637.555.567]
- Killer Cells, Natural [A11.118.637.555.567.537]
- Killer Cells, Lymphokine-Activated [A11.118.637.555.567.537.500]
- Hemic and Immune Systems [A15]
- Blood [A15.145]
- Blood Cells [A15.145.229]
- Leukocytes [A15.145.229.637]
- Leukocytes, Mononuclear [A15.145.229.637.555]
- Cytokine-Induced Killer Cells [A15.145.229.637.555.283]
- Killer Cells, Lymphokine-Activated [A15.145.229.637.555.283.500]
- Lymphocytes [A15.145.229.637.555.567]
- Killer Cells, Natural [A15.145.229.637.555.567.537]
- Killer Cells, Lymphokine-Activated [A15.145.229.637.555.567.537.500]
- Immune System [A15.382]
- Leukocytes [A15.382.490]
- Leukocytes, Mononuclear [A15.382.490.555]
- Cytokine-Induced Killer Cells [A15.382.490.555.283]
- Killer Cells, Lymphokine-Activated [A15.382.490.555.283.500]
- Lymphocytes [A15.382.490.555.567]
- Killer Cells, Natural [A15.382.490.555.567.537]
- Killer Cells, Lymphokine-Activated [A15.382.490.555.567.537.500]
Below are MeSH descriptors whose meaning is more specific than "Killer Cells, Lymphokine-Activated".
This graph shows the total number of publications written about "Killer Cells, Lymphokine-Activated" by people in Harvard Catalyst Profiles by year, and whether "Killer Cells, Lymphokine-Activated" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 0 | 1 |
| 1994 | 2 | 0 | 2 |
| 1995 | 3 | 1 | 4 |
| 1996 | 1 | 0 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2007 | 1 | 1 | 2 |
| 2008 | 0 | 1 | 1 |
Below are the most recent publications written about "Killer Cells, Lymphokine-Activated" by people in Profiles.
-
CD16+CD56+ cells are a potential culprit for hematuria in IgA nephropathy. Clin Exp Nephrol. 2015 Apr; 19(2):216-24.
-
Inducing anti-tumor cytokines and an immune response in melanoma by inhibition of MIA using the peptide AR71. Eur J Dermatol. 2013 Nov-Dec; 23(6):820-5.
-
T-bet plays a key role in NK-mediated control of melanoma metastatic disease. J Immunol. 2008 Jun 15; 180(12):8004-10.
-
Immunotherapy of malignant brain tumors. Immunol Rev. 2008 Apr; 222:70-100.
-
High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother. 2007 Sep; 30(6):596-606.
-
GalT-KO pigs: is the cup half empty or half full? Transplantation. 2007 Jul 15; 84(1):12-4.
-
Expression, processing and transcriptional regulation of granulysin in short-term activated human lymphocytes. BMC Immunol. 2007 Jun 27; 8:9.
-
Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab. Clin Cancer Res. 2007 Apr 15; 13(8):2392-9.
-
Cytolytic cells induce HMGB1 release from melanoma cell lines. J Leukoc Biol. 2007 Jan; 81(1):75-83.
-
Gs protein-coupled adenosine receptor signaling and lytic function of activated NK cells. J Immunol. 2005 Oct 01; 175(7):4383-91.